کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2771990 1151789 2007 9 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Optimal Duration of Antibiotic Therapy in Vertebral Osteomyelitis
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی بیهوشی و پزشکی درد
پیش نمایش صفحه اول مقاله
Optimal Duration of Antibiotic Therapy in Vertebral Osteomyelitis
چکیده انگلیسی

ObjectivesTo compare the risk of relapse of vertebral osteomyelitis (VO), according to the duration of antibiotic therapy (≤6 weeks versus >6 weeks).MethodsWe performed a 10-year retrospective study to assess the risk of VO relapse and to verify that this risk was not enhanced in patients who received 6 weeks of antibiotic therapy (Group 1) as compared with those who received a longer treatment (Group 2). VO was diagnosed based on clinical manifestations, magnetic resonance imaging and/or computed tomography findings, and isolation of a pyogenic organism in blood cultures and/or a discovertebral biopsy. Relapse was diagnosed based on isolation of the same organism in blood cultures and/or a discovertebral biopsy. Outcome was evaluated 6 months post-treatment and in December 2004.ResultsGroup 1 included 36 patients (mean age, 58 ± 15 years) and Group 2 included 84 patients (mean age, 67 ± 15 years) (P = 0.003). Clinical data and microorganisms were comparable in the 2 groups. In the first 6 months, 6 (5%) patients died (Group 1, n = 2; Group 2, n = 4), and 5 (4%) in Group 2 relapsed, 2 with recurrent VO and 3 with recurrent bacteremia. In 2004, 91 patients were evaluated (mean follow-up, 40.6 ± 31 months): 77 (85%) were cured, 13 (14%) died (Group 1, n = 3; Group 2, n = 10), 1 had VO due to a different microorganism (Group 2), and no long-term relapses occurred.ConclusionOur results suggest that antibiotic therapy of VO could be safely shortened to 6 weeks without enhancing the risk of relapse.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Seminars in Arthritis and Rheumatism - Volume 36, Issue 5, April 2007, Pages 269–277
نویسندگان
, , , , , , , , , , , ,